Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CASGEVY™ safely and effectively. See full prescribing information for CASGEVY CASGEVY (exagamglogene autotemcel), suspension for intravenous infusion Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-other
CASGEVY is indicated for the treatment of patients aged 12 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises transfusion-dependent β-thalassemia (TDT)
- generic_name
- exagamglogene autotemcel
- product_names
- exagamglogene autotemcel
- ndc
- 51167-290, 51167-290-01, 51167-290-09
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en